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Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to
treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral
ibandronate has been developed to overcome this problem.
Objective: To confirm the 1 year results and provide more extensive safety and tolerability information for
once-monthly dosing by a 2 year analysis.
Methods: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of
once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral
fracture risk in comparison with placebo.
Results: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone
mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-
monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly
regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better
(p,0.001). Substantial increases in proximal femur (total hip, femoral neck, trochanter) BMD were seen;
150 mg produced the most pronounced effect (p,0.05 versus daily treatment). Independent of the
regimen, most participants (70.5–93.5%) achieved increases above baseline in lumbar spine or total hip
BMD, or both. Pronounced decreases in the biochemical marker of bone resorption, sCTX, observed in all
arms after 3 months, were maintained throughout. The 150 mg regimen consistently produced greater
increases in BMD and sCTX suppression than the 100 mg and daily regimens. Ibandronate was well
tolerated, with a similar incidence of adverse events across groups.
Conclusions: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment.
Once-monthly administration may be more convenient for patients and improve therapeutic adherence,
thereby optimising outcomes.
O
steoporosis is a chronic, age related condition. Bone
loss occurs without presenting symptoms and is often
only diagnosed as a result of a fracture. An estimated
one in three women will sustain an osteoporosis related
fracture in their lifetime.1 These fractures result in increased
disability and excess mortality. In 2003, the estimated total
direct cost of osteoporosis related fractures in the European
Union during the first year after fracture was J25 billion.2 In
the USA, the annual expenditure for care of osteoporotic
fractures was estimated to be $17.5 billion in 2002 (adjusted
from 1995 to 2002 dollars).3
Oral bisphosphonates produce clinically significant reduc-
tions in the risk of new vertebral fractures4–8 and are the
current mainstay of treatment for postmenopausal osteo-
porosis. However, long term treatment is required for optimal
and sustained benefit.9 10 Long term adherence to any
treatment, regardless of the disease, is known to be poor.11
Based on evidence from other chronic diseases,12 it is
expected that reducing the burden of administration by
further decreasing the dosing frequency of bisphosphonates
may improve adherence.13 This is seen in the significant
advantage provided by weekly over daily dosing.14216
However, a growing body of evidence suggests that real-
world adherence to weekly oral bisphosphonates remains
suboptimal. Indeed, recent studies suggest that persistence
rates with weekly bisphosphonates at 1 year are less than
50%.14–16 Poor therapeutic adherence results in smaller
decreases in bone turnover, reduced bone mineral density
(BMD) gains, and a greater risk of fractures.17–19
Ibandronate (Boniva) is a potent, nitrogen-containing
bisphosphonate that can be administered with extended
intervals between doses.20 21 Ibandronate is approved for the
treatment of postmenopausal osteoporosis based on its
demonstration of significant vertebral antifracture efficacy
when administered orally, either daily or intermittently with
extended intervals between doses of .2 months, with a
safety and tolerability profile similar to placebo.4 5 A dose-
response relationship has been demonstrated with once-
monthly oral ibandronate, in a randomised, double blind,
dose finding, phase I study (Monthly Oral Pilot Study
(MOPS)), for systemic exposure (area under the curve and
maximum concentration) and reduction of bone resorption22;
confirming the feasibility of once-monthly oral ibandronate
dosing.
Abbreviations: BMD, bone mineral density; CI, confidence interval;
DXA, dual energy x ray absorptiometry; GI, gastrointestinal; ITT,
intention to treat; MOBILE, Monthly Oral iBandronate In LadiEs; PP, per-
protocol; sCTX, C-telopeptide of the a-chain of type I collagen
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On the basis of these positive studies, MOBILE (Monthly
Oral iBandronate In LadiEs) a randomised, phase III, non-
inferiority study was initiated. MOBILE was designed to
compare the efficacy and safety of three once-monthly oral
ibandronate regimens (50 + 50 mg (given on 2 consecutive
days), 100 mg, and 150 mg) with the efficacious and well
tolerated daily oral ibandronate regimen (2.5 mg).4 5 The
1 year results indicated that all the once-monthly ibandro-
nate regimens were at least as effective as the active
comparator, daily ibandronate, producing substantial
increases in lumbar spine and proximal femur (total hip,
femoral neck, trochanter) BMD.23 Furthermore, the once-
monthly regimens had a tolerability profile similar to the
daily regimen. The 1 year analysis also suggested that the
150 mg once-monthly regimen had a more pronounced effect
for all efficacy end points than the 2.5 mg daily and 100 mg
once-monthly regimens, with similar safety and tolerability.
The purpose of this prospective, 2 year analysis was to
confirm the findings of the 1 year efficacy analysis and to




MOBILE was a 2 year, randomised, double blind, parallel
group, phase III, non-inferiority study, conducted in 65
centres in USA, Canada, Mexico, Brazil, Europe, Australia,
and South Africa. The institutional review boards of the
participating centres provided ethical approval of the study.
The study was conducted in accordance with the principles of
the Declaration of Helsinki and International Conference on
Harmonisation of Good Clinical Practice guidelines.
Study participants and medication
All study participants were ambulatory postmenopausal
women, aged 55–80 years and at least 5 years since the
menopause, with osteoporosis (mean lumbar spine (L2–4)
BMD T-score between ,22.5 and .25.0). Further details of
the prespecified inclusion and exclusion criteria have
previously been reported.23 All participants provided written
informed consent.
At enrolment, participants were randomised into one of
four oral ibandronate treatment groups, either 2.5 mg daily,
Ibandronate
50 + 50 mg  monthly
n = 404
Received at least one
dose of trial treatment
and had at least one
follow up assessment
n = 395
Received at least one
dose of trial treatment
n = 400








n = 70 (18%)
AE/death: n = 41
No follow up: n = 3
Refused trt†: n = 20
Other‡: n = 6
Completed 2 years of
treatment
n = 325 (82%)
Received at least one
dose of trial treatment
and had at least one
follow up assessment
n = 396
Received at least one
dose of trial treatment
n = 401





n = 68 (17%)
AE/death: n = 32
No follow up: n = 2
Refused trt†: n = 29
Other‡: n = 5
Completed 2 years of
treatment
n = 328 (83%)
Received at least one
dose of trial treatment
and had at least one
follow up assessment
n = 396
Received at least one
dose of trial treatment
n = 400






Patients randomised: n = 1609
Patients screened: n = 2410
Withdrawn from
treatment
n = 80 (20%)
AE/death: n = 44
No follow up: n = 4
Refused trt†: n = 29
Other‡: n = 3
Completed 2 years of
treatment
n = 316 (80%)
Received at least one
dose of trial treatment
and had at least one
follow up assessment
n = 396
Received at least one
dose of trial treatment
n = 401








n = 74 (19%)
AE/death: n = 37
No follow up: n = 5
Refused trt†: n = 32
Other‡: n = 0
Completed 2 years of
treatment
n = 322 (81%)
Figure 1 Patient disposition. *50 mg on two consecutive days; refused treatment includes ‘‘did not cooperate’’ and ‘‘withdrew consent’’; `other
includes ‘‘insufficient therapeutic response’’, ‘‘early improvement’’, ‘‘violation of selection criteria at entry’’, and ‘‘other protocol violation’’. AE,
adverse event; trt, treatment.
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50 + 50 mg once-monthly (single doses given on 2
consecutive days), 100 mg once-monthly or 150 mg once-
monthly. Participants also received daily or once-monthly
oral placebo to maintain blinding, plus daily elemental
calcium (500 mg) and vitamin D (400 IU) supplements.
Participants were instructed to take their study medication
after an overnight fast (>6 hours) and with 240 ml of plain
water. They were then required to stay upright and fast for at
least 60 minutes after dosing.
Primary efficacy end point
The primary efficacy end point was the change (%) from
baseline in lumbar spine (L2–4) BMD at 1 year, as measured
by dual energy x ray absorptiometry (DXA). The results for
the primary efficacy end point have previously been
reported.23
Secondary efficacy end points
Secondary efficacy end points included the change (%) from
baseline in lumbar spine (L2–4) and proximal femur (total
hip, femoral neck, trochanter) BMD at 2 years, as measured
by DXA. GE Lunar (Madison, WI, USA) or Hologic (Bedford,
MA, USA) instruments were used when performing DXA
scans; scans were assessed by a central BMD reading centre
(Synarc, Portland, USA). Responder analyses, defined as the
percentage of participants maintaining or achieving increases
in lumbar spine BMD, total hip BMD or lumbar spine and
total hip BMD above baseline were carried out. In addition,
the proportion of patients achieving defined increases in
lumbar spine or total hip BMD (>6% and >3%, respectively),
previously associated with vertebral24 and non-vertebral25
antifracture efficacy, was also prospectively evaluated.
The change (%) from baseline in serum concentrations of
the biochemical marker of bone resorption C-telopeptide of
the a-chain of type I collagen (sCTX) was also measured at
2 years. Blood samples for sCTX assessments were taken
immediately before the next scheduled, once-monthly dose,
after an overnight fast (>6 hours), and between 8 am and 10
am. sCTX levels measured in the once-monthly groups
therefore represent the residual magnitude of suppression
at the end of the dosing interval. sCTX assays (Elecsys b-
CrossLaps/serum, Elecsys 2010, Roche Diagnostic, Basel,
Switzerland) were analysed at a central biomarker laboratory
(Synarc, Lyon, France). The proportion of patients respond-
ing to treatment, with sCTX reductions of >50% and >70%
from baseline, was also prospectively identified. The thresh-
old of 50% corresponds with the least significant change
(1.96!2 6 coefficient of variation).26
Safety parameters
Adverse events were continuously monitored throughout the
study. The relationship between treatment and intensity of
all adverse events was also assessed. Clinical vertebral and
non-vertebral fractures were identified symptomatically,
confirmed radiographically, and reported as adverse events.
Laboratory safety variables were analysed at baseline and
every 6 months thereafter. Samples were processed at a
centralised safety laboratory (MDS, Les Ponts de Baillet,
France).
Randomisation
Eligible patients were stratified by centre and baseline BMD
status before randomisation, to ensure comparable distribu-
tion of baseline BMD across the treatment arms. Participants
were randomised using adaptive minimisation via a centra-
lised ‘‘call in’’ system (Interactive Voice Response System,
ClinPhone Ltd, Nottingham, UK).
Statistical analysis
Analysis populations
The per-protocol (PP) population was used as the primary
analysis population for all efficacy measures as this is
considered the most conservative approach to detecting
actual differences among treatments when performing a
non-inferiority analysis.27 The PP population consisted of all
those participants in the intention to treat (ITT) population
who had no major protocol violations at baseline or during
the first year of study. Major violations were categorised as a
baseline lumbar spine (L2–4) BMD T-score .22.5; poor
compliance with treatment; unconfirmed menopausal status;
prohibited concomitant disease or treatment before study;
lack of efficacy data or reliable BMD data. If such violations
occurred during year 2 then data from individual visits were
censored rather than excluding the patient completely from
the analysis.
The ITT population included all participants who were
randomised, received at least one dose of the study drug, and
had at least one efficacy follow up data point. To confirm the
robustness of the PP findings, analyses were also performed
for all efficacy end points using the ITT population. The safety
population included all participants who received at least one
dose of the study drug, including withdrawn participants,
and had at least one follow up assessment.
Analysis of primary efficacy measure at 2 years and
secondary efficacy end points
At 2 years, the change (%) from baseline in lumbar spine
BMD with the once-monthly regimens was compared with











(n = 395) (n = 396) (n = 396) (n = 396)
Age (years) 65.8 66.0 66.2 66.2
Weight (kg) 64.1 64.1 64.0 63.7
Height (cm) 157.1 157.4 157.3 158.0
Body mass index (kg/m2) 25.9 25.8 25.9 25.5
Time since menopause (years) 18.3 18.7 19.1 18.3
History of previous fractures (%)* 48.9 46.3 45.5 47.0
Lumbar spine (L2–4) BMD (g/cm2) 0.755 0.755 0.756 0.754
Lumbar spine (L2–4) BMD (T-score) 23.28 23.28 23.27 23.28
sCTX (ng/ml) 0.49 0.52 0.51 0.50
25-hydroxyvitamin D (ng/ml) 25.7 24.4 25.1 24.7
Results are shown as the mean unless stated otherwise.
*:Percentage of patients; median value.
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the change with the daily regimen using a non-inferiority
test. Non-inferiority margins for the analysis of change (%)
from baseline in lumbar spine BMD were based on 30% of the
minimum treatment effect observed between daily oral
ibandronate and placebo after 2 years in a prior clinical
study (BONE).5 On this basis, non-inferiority could be
concluded if the lower boundary of the two sided 95%
confidence interval (CI) for the difference in the means
between the once-monthly and daily regimens was >21.3%
at 2 years.
If non-inferiority was demonstrated for the primary
efficacy measure then superiority of the once-monthly
regimens over the daily regimen was tested using analysis
of variance, controlling for geographic location and baseline
BMD. Changes (%) from baseline in proximal femur BMD
and sCTX were summarised only, with 95% CIs for the
difference in the mean BMD and median sCTX values
between the once-monthly and daily regimens calculated.
The percentage of participants responding to treatment was
compared using a x2 test.
Analysis of safety variables
All adverse events reported throughout the 2 year study
period were included in the safety analysis. All of the
observed adverse events were evaluated by standardised
tabulation of the prevalence and incidence.
RESULTS
Patient disposition and baseline characteristics
In accordance with the original sample size calculation,23
1609 postmenopausal women were randomised into the
study. Figure 1 shows the disposition of patients. A total of
1291 participants completed 2 years of treatment, with 292
(18.1%) participants withdrawing from the study. Most
patients withdrew from the study during the first 3 months,
regardless of treatment group.
The number of participants included in the PP population
was 1277; the main reasons for excluding patients from the
PP population, based upon 1 year data, were non-compliance
with daily or monthly schedule (,17%), and no reliable BMD
values (,6%). Data were also censored for non-compliance
with daily study medication (,8%) or the monthly dosing
schedule during year 2 (,7%). The number of participants
included in the ITT population was 1572. Because, all patients
took both daily and monthly tablets, these measures of
compliance do not allow conclusions on differences in
therapeutic adherence.
Baseline patient characteristics, such as age, years since
menopause, history of fractures, bone turnover markers, and
lumbar spine BMD, were well balanced across the treatment
groups (table 1).
Efficacy analysis
Substantial increases in lumbar spine (L2–4) BMD were seen
in all treatment arms (fig 2). Compared with baseline, mean
increases in lumbar spine BMD were 5.3% (95% CI 4.8 to 5.9),
5.6% (95% CI 5.1 to 6.1), and 6.6% (95% CI 6.0 to 7.1) in the
50 + 50 mg, 100 mg, and 150 mg once-monthly groups,
respectively, compared with 5.0% (95% CI 4.4 to 5.5) in the
daily treatment group. All once-monthly regimens were
prospectively proved to be non-inferior, and thus shown to
be at least as effective as the daily regimen (fig 3).
Furthermore, 150 mg once-monthly was prospectively proved
to be better than the daily regimen (p,0.001). A post hoc
analysis showed that for the mean increase in lumbar spine
(L2–4) BMD the 150 mg once-monthly ibandronate regimen




























50 + 50 mg (n = 291)
150 mg (n = 289)
Figure 2 Change (%) from baseline in
lumbar spine and proximal femur BMD
at 2 years (PP; mean (95% CI)).
*p,0.001 versus daily treatment;
p,0.05 versus daily treatment.
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100 mg – 2.5 mg
50 + 50 mg – 2.5 mg
Figure 3 Forest plot of the difference in the means (95% CI) of the mean
change (%) from baseline in lumbar spine (L2–4) BMD between the once-
monthly and daily oral ibandronate regimens after 2 years (PP),
demonstrating that all once-monthly regimens are non-inferior to the
2.5 mg daily dose regimen.
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was also significantly better than the 100 mg once-monthly
treatment (p = 0.011).
The ITT analysis confirmed these findings; mean increases
in lumbar spine (L2–4) BMD were 5.3% (95% CI 4.7 to 5.8),
5.3% (95% CI 4.8 to 5.8), and 6.4% (95% CI 5.9 to 6.9) in the
50 + 50 mg, 100 mg, and 150 mg once-monthly groups,
respectively, compared with 4.8% (95% CI 4.3 to 5.3) in the
daily treatment group. All the once-monthly regimens were
non-inferior to the daily regimen, and the 150 mg once-
monthly regimen was superior (p,0.001). The 150 mg once-
monthly ibandronate regimen was also found, by post hoc
analysis, to be statistically better than the 100 mg treatment
for mean increases in lumbar spine (L2–4) BMD (p = 0.003).
Large increases in proximal femur BMD (total hip,
trochanter, and femoral neck) were also seen in all treatment
arms (fig 2). As at the lumbar spine, the most substantial
increases in hip BMD were seen with the 150 mg regimen.
From the 95% CIs for the difference between the means
associated with the 100 mg and 150 mg regimens compared
with the daily regimen, it was concluded that both once-
monthly regimens produced better increases in total hip,
femoral neck, and trochanter BMD (p,0.05) (fig 2).
Comparable findings were obtained from the ITT analysis,
with substantial increases in proximal femur BMD reported
for all ibandronate treatment regimens. The results of the
superiority analysis were replicated with the ITT population,
the one exception being the 100 mg regimen, which was no
better than the daily regimen for increases in femoral neck
BMD.
Independent of the ibandronate dosing regimen, lumbar
spine BMD, total hip BMD, or both, increased above baseline
in most participants (70.5–93.5%) (fig 4). In the 150 mg
once-monthly oral ibandronate group response rates at
2 years were consistently over 87% for increases in lumbar
spine or total hip BMD above baseline, and were significantly
greater than for the daily treatment group (p(0.004). A post
hoc analysis found that the incidence of responders with
increases above baseline in lumbar spine BMD or lumbar
spine and total hip BMD in the 150 mg once-monthly
treatment group was significantly greater than in the
100 mg once-monthly treatment group (p,0.01).
Large proportions of patients also achieved target increases
in lumbar spine (>6%; 35.4–54.3%) or total hip (>3%; 40.4–
65.1%) BMD (fig 4). Overall, greater proportions of patients
in the once-monthly treatment arms achieved target
increases in BMD than in the daily treatment arm, with the
highest responder rates consistently seen with the 150 mg
regimen (p,0.05 versus daily for all responder analyses;
fig 4).
The incidence of responders to treatment was similar in the
ITT analysis population; the 150 mg once-monthly treatment
group had a significantly increased percentage of patients
with lumbar spine BMD, total hip BMD, or both, above
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Figure 4 Participants (%) considered
responders to daily or once-monthly













2.5 mg (n = 221)
50 + 50 mg (n = 215)
100 mg (n = 211)
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Figure 5 Time course of median (95% CI) change (%) from baseline in
sCTX (PP).
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baseline and with target increases (lumbar spine >6%, and
total hip >3%) in comparison with the 2.5 mg daily
treatment group (p(0.01).
In all the treatment arms, the pronounced decreases in
sCTX seen after 3 months23 were maintained throughout the
2 year study period (fig 5). Compared with baseline, median
sCTX levels decreased by 56.1%, 60.5%, and 67.7% in the 50 +
50 mg, 100 mg, and 150 mg arms, respectively, compared
with 61.5% in the daily group at 2 years.
The percentage of patients with a >50% decrease in sCTX
from baseline was greater in the 150 mg once-monthly
treatment group (78.7%), than in the 50 + 50 mg (60.9%),
100 mg (63.5%), and 2.5 mg daily treatment groups (65.6%,
p = 0.002). The proportion of patients with a >70% decrease
in sCTX from baseline followed the same pattern: 35.3%,
27.0%, 35.1%, and 48.1% for the 2.5 mg, 50 + 50 mg, 100 mg,
and 150 mg treatment groups respectively. A significantly
greater proportion of patients responded to the 150 mg once-
monthly regimen than to the daily regimen (p = 0.006). The
ITT population analysis found comparable results for both
levels of sCTX suppression.
Safety parameters
A similar proportion of patients in the once-monthly and
daily treatment arms withdrew from treatment. The numbers
of withdrawals (not including deaths) due to adverse events
were evenly balanced across the treatment arms: 31 (8%), 42
(11%), 36 (9%), and 39 (10%) in the 50 + 50 mg, 100 mg,
150 mg monthly, and daily treatment groups, respectively
(fig 1).
The incidence of adverse events, drug related adverse
events, and drug related adverse events leading to with-
drawal was well balanced across the treatment arms (table 2).
The most commonly reported adverse events, irrespective of
relationship to treatment, were hypertension, dyspepsia and
arthralgia; occurring with similar frequency across the
treatment groups, and consistent with the population under
study. A low rate of serious adverse events was observed.
Only eight treatment related serious adverse events were
reported during the 2 year study period. These were: gastric
ulcer (two cases), duodenal ulcer, erosive duodenitis, gastric
ulcer haemorrhage, gastritis haemorrhagic, melaena, and
liver disorder. Most adverse events were considered unrelated
to treatment and resulted in only a small number of patient
withdrawals (table 2). In total, six deaths occurred during the
study period, two during the second year, all of which were
unrelated to treatment.
The incidence of upper gastrointestinal (GI) adverse events
was similar across the treatment arms (20–26%; table 2), and
events were generally mild to moderate in severity. When
only those who were taking non-steroidal anti-inflammatory
drugs and/or aspirin at baseline (23.6–31.2%) were consid-
ered the number reporting upper GI events was slightly
increased. However, the incidence of upper GI events was
well balanced across the once-monthly and daily treatment
arms. In particular, there was no evidence that treatment for
2 years with once-monthly doses of 150 mg led to an
increased incidence in upper GI adverse events compared
with the other once-monthly or daily treatment groups.
The number of patients with diagnosed flu-like illness
considered by the investigator to be possibly or probably
related to treatment was 1 (0.3%), 4 (1.0%), 5 (1.3%), and 13
(3.3%) for the 2.5 mg, 50 + 50 mg, 100 mg, and 150 mg
groups, respectively. Such events were typically of short
duration (1–4 days), mild to moderate in intensity, and
associated with the first administered dose only. None of the
patients experiencing flu-like illness during year 1 had a
recurrence of symptoms during year 2 of the study.
The number of clinical osteoporotic fractures was similarly
low across the treatment groups (table 2). Overall, there were
no clinically relevant changes in the mean haematology or
clinical chemistry values during treatment in either the daily
or monthly treatment groups.
DISCUSSION
MOBILE is a randomised, double blind, comparative, non-
inferiority trial with the primary efficacy end point defined as
the change (%) from baseline in lumbar spine BMD after
1 year.23 The data were analysed at 2 years to confirm the
1 year efficacy and safety findings, and to provide more
extensive information about once-monthly oral ibandronate
for use in the treatment of postmenopausal osteoporosis.
The 2 year analysis categorically confirms the findings and
conclusions drawn from the 1 year result.23 All the once-
monthly regimens produced substantial increases in lumbar
spine BMD and were shown by a non-inferiority test to be at
least as effective as the daily oral ibandronate regimen at 1
and 2 years. As at 1 year, the increases in lumbar spine BMD
observed in the 150 mg treatment arm were prospectively
proved to be better than the daily regimen (p,0.001).
In addition to improvement in spinal BMD, the once-
monthly regimens produced significant increases in proximal
femur (total hip, femoral neck, trochanter) BMD by the end
of the 2 year study period, with the greatest gains observed
with the 150 mg regimen (p,0.05). The 150 mg once-
monthly regimen consistently produced substantial improve-
ments in proximal femur BMD over and above those seen
with the daily regimen.










(n = 395) (n = 396) (n = 396) (n = 396)
Overall
Any adverse event 302 (76.5) 313 (79.0) 318 (80.3) 317 (80.1)
Any drug related adverse event: 128 (32.4) 119 (30.1) 143 (36.1) 146 (36.9)
Leading to withdrawal 30 (7.6) 20 (5.1) 26 (6.6) 27 (6.8)
Any serious adverse event 38 (9.6) 54 (13.6) 55 (13.9) 45 (11.4)
Any drug related serious adverse
event: 2 (0.5) 2 (0.5) 3 (0.8) 1 (0.3)
Leading to withdrawal 1 (0.3) 1 (0.3) 0 1 (0.3)
Adverse events of special interest
Upper GI adverse events 90 (22.8) 79 (19.9) 102 (25.8) 89 (22.5)
Clinical osteoporotic fractures 24 (6.1) 29 (7.3) 24 (6.1) 27 (6.8)
Results are shown as No (%).
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The increases in BMD are further supported by the marked
decreases in sCTX seen in all treatment regimens.
Pronounced decreases in sCTX were seen as early as
3 months23 and were maintained throughout the 2 year
study period.
The prespecified responder analyses consistently demon-
strated that a significantly larger proportion of postmeno-
pausal women receiving 150 mg once-monthly ibandronate
achieve increases in lumbar spine and/or total hip BMD and
decreases in sCTX of a defined magnitude after 2 years than
with the daily regimen. This is particularly important
considering that increases in vertebral BMD and decreases
in biochemical markers of bone are both independently
predictive for antifracture efficacy.24 25 28
After the second year of treatment, the safety profile of the
daily and once-monthly regimens was shown to be favour-
able and consistent with that reported after 1 year.23 All
ibandronate regimens were generally well tolerated, with a
similar incidence of adverse events and serious adverse
events across the treatment groups. No upper GI safety and
tolerability concerns were identified; the incidence was low
and comparable across the once-monthly and daily treatment
arms, and no clinically relevant imbalances were observed
even in patients receiving concomitant non-steroidal anti-
inflammatory drugs and/or aspirin. The 2 year results
furthermore confirmed a low incidence of flu-like illness, of
similar magnitude to that seen with other oral bispho-
sphonates,29 30 with events being of short duration and most
frequently associated with the initial administration only.
Overall, no relevant differences in safety and tolerability were
seen between the once-monthly and daily regimens. The
findings of the overall safety and tolerability analysis are fully
aligned with the favourable profile for oral ibandronate
found in prior clinical studies, in which a safety profile
similar to placebo was observed, independent of the dosing
regimen.4
For all efficacy end points, the 150 mg once-monthly
regimen provides additional benefits in comparison with the
daily and 100 mg once-monthly regimens, without compro-
mising safety and tolerability. A relative risk reduction in the
incidence of new vertebral fractures of 62%, associated with
significant increases in lumbar spine and suppression of bone
turnover markers, has been demonstrated for daily oral
ibandronate.4 5 The 150 mg once-monthly regimen studied in
MOBILE provided marked gains in lumbar spine BMD and
decreases in sCTX over and above those demonstrated with
the daily oral regimen.
A once-monthly oral ibandronate regimen may provide
further benefits through potentially greater adherence to
treatment. The recently reported strong preference of patients
for a once-monthly bisphosphonate dosing regimen13 is
expected to translate into improved therapeutic adherence
and suggests that once-monthly ibandronate dosing could
provide additional adherence benefits over current dosing
strategies, such as weekly treatment. Once-monthly iban-
dronate is likely to provide an effective and patient-friendly
treatment option in postmenopausal osteoporosis.
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